





Presented by Management Forum

GMP Principles in Vaccine Manufacturing

10-11 September 2025 + 10-11 December 2025

Vaccinology continues to advance and mature impressively, both in developing new and improved vaccines and in administering vaccines to prevent disease. On this course, explore GMP principles in vaccine manufacturing. کے Format: Live online ()

CPD: 12 hours for your records



Certificate of completion

Course overview

In this two-day training, the history of vaccines and adverse events will be discussed, information will be presented about various vaccine types and production platforms, raw material, production, quality control, quality assurance, storage, and distribution processes in a GMP-compliant vaccine facility will be explained to the participants with examples and real-time scenarios.

With the advent of vaccine development, life expectancy has increased and the quality of life has improved visibly. Vaccinology continues to advance and mature impressively, both in developing new and improved vaccines and in administering vaccines to prevent disease. Some vaccines used today were developed in the 1940s and 1950s and have remained virtually unchanged. This situation is not surprising for experts who can read the pharmaceutical industry and the ecosystem dynamics that develop around it well. Just like small molecule chemical drugs, to maximise the life cycle of a vaccine, the most important prerequisite is that the raw materials, components, and consumables are in the same composition and consistency from the beginning.

The SARS-CoV-2 pandemic highlighted the importance of vaccines to control the consequences of COVID-19. Most of these GMP facilities are in the EU, USA, China, and European countries. To facilitate the access of these types of products to the rest of the world, the expansion of production capacities and installation of new GMP production plants is essential.

To optimise vaccine production processes and develop efficient and effective processes, it is necessary to continuously supply quality raw materials from reliable suppliers that have been audited and approved by internationally recognised, certified, competent, and experienced GMP auditors.

Compliance with cGMP requires setting up a quality system (QS), which will vary in complexity according to the size of the company. However, there are some basic principles to be followed in terms of design, manufacture, validation, quality control, packaging, labelling, and storage. As it is known, the use of living organisms in the vaccine manufacturing process brings safety requirements to the fore. This situation points to a more complex structure outside of traditional drug production.

One of the most obvious risks in vaccine production is undoubtedly crosscontamination. In such a risky environment, the importance of ensuring the cleanliness and safety of the area, equipment, and personnel and cleaning and disinfection increases. GMP compliance and safety requirements brought about by the use of negative and positive pressure rooms are some of the challenges of vaccine production. Although innovative approaches such as mRNA technology seem to minimise some risks, there is still a lot to be done.

This course will provide an excellent opportunity to become fully briefed on the GMP principles in vaccine manufacture and enable participants to discuss the techniques with an expert in this field.

Benefits of attending

On this course, participants will:

- **Gain** information about vaccine manufacturing technologies
- **Understand** the advantages and disadvantages of different production platforms
- Learn the differences between vaccine and traditional drug production
- See how to adapt risk management principles and contamination control strategy to a facility
- **Explore** detailed information about biosafety cabinets and their uses
- Look at insights into the principles of raw material controls, production, quality control, release, storage and distribution in a GMPcompliant vaccine production facility
- Focus on examples of how difficulties in vaccine production can be overcome
- Appreciate the chance to take a closer look at viral, subunit and mRNA GMP applications
- **Examine** concepts such as viral safety, stability and TSE in vaccines through examples
- Assess the information about upstream, downstream and cell banks
- Form an opinion on the layout plan of a vaccination facility

Who should attend

Personnel from these job departments will benefit from the course:

- Quality Control
- Quality Assurance
- Manufacturing (Upstream & Downstream)
- Engineering
- GMP Compliance
- Audit
- Suppliers to Vaccine Manufacturers



Programme

Day 1

History of vaccines

- Why and how were vaccines developed?
- What are the technological developments from the first vaccine to today?
- Making, purifying, formulating

Vaccine types and manufacturing platforms

- Live attenuated vaccine types
- Non-live vaccine types •
- New types of vaccines

Viral vector vaccines & GMP

- Media & inoculum
- Cell growth
- Clarification
- UF/DF
- Purification
- UF/DF
- Formulation, sterile filtration

Subunit vaccines & GMP

- Media & inoculum
- Cell arowth
- NA removal
- Clarification
- Chromatography
- UF/DF
- Virus removal •
- Formulation, sterile filtration •

mRNA vaccines & GMP

- Plasmid
- Chromatography •
- In-vitro transcription •
- Chromatography
- Capping •
- Chromatography •
- UF/DF
- Encapsulation
- Formulation, sterile filing

Vaccine components

- Adjuvants
- Stabilisers
- Buffers •
- Solvents •
- Preservatives •
- Animal derived ingredients •

Group exercise - health authority inspection citations about vaccine manufacturers

Traditional platforms for protein-based vaccines

- Bacteria
- Yeast
- Insect
- Mammalian
- New approaches •

Day 2

Upstream processing essentials

- Example vaccine antigens
- Critical quality attributes
- Critical process parameters
- Critical material attributes
- How to maintain stable cell lines?

Downstream processing essentials

- Purification principles
- Which chromatography method to choose? How many? •
- Viral clearance essentials •
- Filtration methods best practices

Stability of vaccines

- Stability concerns
- Buffers and stabilisers in vaccine stability

Lyophilisation of vaccines

- Lyophilisation and validation
- New Annex 1 expectations for Lyophilises

Group exercise - how to select a final container for a vaccine?

Quality control of vaccines

- Which tests are performed?
- Technology transfer issues
- Method validation
- Analytic requirements on vaccine manufacturing

Manufacturing constraints of vaccines

- Purity vs cost
- Central vs distributed manufacturing
- Vaccine manufacturing failures
- Timing of investments
- GMP deficiencies of vaccine manufacturing

How to design a vaccine facility

- Cleanroom design rules
- Containment approaches
- Risk-based principles of design purposes
- Segregation
- Hygiene •
- Airlocks & pressure differentials •
- Personal gowning
- Contamination control strategy

Presenter



Mustafa Edik

Mustafa Edik is an Independent GMP Consultant and Auditor.

After graduating as a Chemist from university, Mustafa began his 25 year plus career as a Laboratory Supervisor at Bayer, a German Pharmaceutical Company. After 15 years of working as a Quality Assurance Assistant Manager, Laboratory Supervisor, Pharmaceutical Quality Management Systems, and GMP Lead Auditor, he decided to continue his career as a Consultant. He has served the Turkish Atomic Energy Authority (TAEA) as Principal GMP Auditor and Consultant for 6 years. TAEA was audited by the Republic of Turkey Ministry of Health and granted GMP Certificate for 5 Radiopharmaceuticals. This success has won great acclaim from all health authorities and industry.

He has prepared and presented various training courses and workshops to more than 8000 individuals from 150 International and local Pharmaceutical, Medical Device, and Cosmetics companies on GMP, GDP and Pharmaceutical Quality Management Systems. He has taken part in several International Pharmaceutical Facility Establishment projects as GMP Consultant and has also set up various Quality Management Systems for Local Pharmaceutical and Medical Device Companies.

While he was the Vice President of Quality and Technical Operations at a Quality Academia Training and Consultancy firm, he acquired and converted it into a 100 % Turkish Company. As the only IRCA Certificated Pharmaceutical Quality Management Systems and GMP Lead Auditor in Turkey, he currently conducts API, Excipient, Packaging Materials Suppliers and Manufacturers, Third Party Logistics Service Providers, Sterile and Non-Sterile Manufacturing Facilities Audits according to FDA, EMA, PIC /S, TMMDA, MHRA, TGA Health Canada, and WHO regulations and guidelines.

He finished his second university degree in Biopharmaceutical Sciences BSc (Hons) at Atlantic Technological University - Ireland. He is the author of chapter 6 of the book published by PDA named "Good Distribution Practices" and his new book on 'GMP Audits in Pharmaceutical and Biotechnology Industires' will be published by Taylor & Francis in June 28, 2024.

Course dates

10-11 September 2025	Live online 09:30-16:30 UK (London) (UTC+01) Course code 15227	GBP 1,299 1,499 EUR 1,819 2,099 USD 2,087 2,399 Until 06 Aug
10-11 December 2025	Live online 09:30-16:30 UK (London) (UTC+00) <i>Course code 15308</i>	GBP 1,299 1,499 EUR 1,819 2,099 USD 2,087 2,399 Until 05 Nov

How to book

Online:

\bigoplus

ipi.academy/2840

Alternatively contact us to book, or if you have any queries:

Email:

info@ipiacademy.com

Phone: +44 (0)20 7749 4749

Discounts

- Booking more than one delegate on any one date qualifies for a **30% discount** on the second and subsequent places.
- Most events qualify for an early booking discount prior to 6 weeks before the course date. Be sure to check on our website, where the latest discounts will be shown.

Further information

Fee

The fee includes all meals and refreshments for the duration of the course (for venue-based courses) and a complete set of course materials (provided electronically). If you have any particular requirements, please advise customer services when booking.

Please note

IPI Academy (and our training partners) reserve the right to change the content and timing of the programme, the speakers, the date and venue due to reasons beyond their control. In the unlikely event that the course is cancelled, we will refund the registration fee and disclaim any further liability.

Terms and conditions

The rest of the our terms, the event cancellation policy and the terms and conditions are on our website, please visit ipi.academy/content/terms-and-conditions



Run this programme in-house for your whole team

Coming to IPI Academy for your in-house training provides an all-inclusive service which gives you access to a wide variety of content, learning platforms and delivery mechanisms as well as your own personal training adviser who will work with you from the initial enquiry through to feedback and follow-up after the programme.

With over 600 trainers, all practitioners and experts across a huge range of fields, we can provide the training you need, where you need it, when you need it, and at a price which suits your budget. Our approach to tailored learning and development consists of designing and delivering the appropriate solution for each client.

For your FREE consultation and to find out more about how we can work with you to solve your training needs, please contact our training advisers:



ALEKSANDRA BEER Tel: +44 (0)20 7749 4749 Email: inhouse@ipiacademy.com



YESIM NURKO Tel: +44 (0)20 7749 4749 Email: inhouse@ipiacademy.com

III IPI Academy

IPI Academy is a training initiative of Falconbury and Management Forum; leading providers of industry training for over 30 years, based in the UK.

10-12 Rivington Street London EC2A 3DU

ipi.academy Tel: +44 (0)20 7749 4749 Email: info@ipiacademy.com

